NIAID conducts and supports research to better understand, treat, and ultimately prevent infectious and immune-mediated diseases. For more than 60 years, NIAID research has led to new therapies, vaccines, diagnostic tests, and other technologies that have improved the health of millions of people in the United States and abroad. This page highlights notable scientific advances made by NIAID laboratories and NIAID-funded researchers.
Selected NIAID Science News Highlights of 2020
In 2020, NIAID and its global partners rapidly leveraged their scientific infrastructure and expertise to conduct critical basic, preclinical, and clinical research to address the coronavirus disease 2019 (COVID-19) pandemic. Although considerable challenges remain, scientists have made enormous strides this year in understanding, preventing, and treating COVID-19. Other research brought us closer to a new option for HIV prevention, a shorter treatment regimen for drug-susceptible tuberculosis, and a potential new eczema treatment, among many other advances. View the Selected NIAID Science News Highlights of 2020.
Selected NIAID Science News Highlights of 2019
In 2019, research at NIAID and NIAID-funded institutions accelerated progress toward development of a universal flu vaccine, enhanced knowledge of organ transplantation among people with HIV, and provided new tools for studying human prion diseases. Scientists also made advances in treating Ebola, developing gene therapy for a rare immunologic disorder, and understanding the causes of acute flaccid myelitis. In addition, NIAID made strides toward ending the HIV epidemic in the United States and preventing tuberculosis. View the Selected NIAID Science News Highlights of 2019.
